Dr. Ferguson is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3401 N Broad St
Philadelphia, PA 19140Phone+1 215-707-3040Fax+1 215-707-8235
Education & Training
- University of Pennsylvania Health SystemResidency, Neurology, 2002 - 2006
- University of Florida College of MedicineClass of 2001
Certifications & Licensure
- PA State Medical License 2006 - 2014
Publications & Presentations
PubMed
- Serious Neurologic Adverse Events in Tofersen Clinical Trials for Amyotrophic Lateral Sclerosis.Alexandra Lovett, Sowmya Chary, Suma Babu, Gaëlle Bruneteau, Jonathan D Glass
Muscle & Nerve. 2025-02-27 - Safety, tolerability, and pharmacokinetics of antisense oligonucleotide BIIB078 in adults with C9orf72-associated amyotrophic lateral sclerosis: a phase 1, randomised,...Leonard H van den Berg, Jeffrey D Rothstein, Pamela J Shaw, Suma Babu, Michael Benatar
The Lancet. Neurology. 2024-09-01 - 274 citationsTrial of Antisense Oligonucleotide Tofersen forALS.Timothy M Miller, Merit E Cudkowicz, Angela Genge, Pamela J Shaw, Gen Sobue
The New England Journal of Medicine. 2022-09-22
Authored Content
- Phase 1–2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALSJuly 2020
- Phase 1–2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALSJuly 2020
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: